Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE: 600671)
Health Care · Pharmaceuticals · CN
CN¥20.51
-5.44% today · +3.6% 1Y
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE: 600671) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $371.55M and employs 392 people.
Over the last twelve months the share price has gained 3.6%, trading between 15.70 and 23.44.
Tweenvest scores Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd across four factors: quality 49/100, value 29/100, growth 14/100. Its strongest factor is quality.
600671 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $371.55M
- Revenue (TTM)
- $29.55M
- P/E
- 152.84
- EPS
- 0.13
- Dividend yield
- —
- Beta (5Y)
- 0.01
- 52-week high
- CN¥23.44
- 52-week low
- CN¥15.70
- Avg volume (3M)
- —
- Shares outstanding
- 121.78M
- Employees
- 392
- Next earnings
- —
About Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, a company founded in 1958 and based in Hangzhou, China, operates a multifaceted business primarily focused on the pharmaceutical sector. Through its various subsidiaries, the company specializes in both the production and distribution of medicines throughout China. Its extensive product range includes the manufacturing and sale of a diverse array of pharmaceuticals and health-related goods. These encompass various dosage forms such as tablets, granules, pills, mixtures, oral liquids, syrups, eye drops, and soft capsules, as well as a selection of health foods. Beyond finished products, Hangzhou TianMuShan is also involved in the trade of raw materials like menthol and peppermint oil. The company also offers a comprehensive selection of traditional Chinese medicine, including prepared formulas, individual herbal pieces, and fresh herbs. Furthermore, it provides specialized medical services such as custom decoction preparation and delivery, herbal slicing and powder grinding, and traditional Chinese medicine diagnosis and treatment. In addition to its core pharmaceutical activities, the enterprise has diversified into other ventures, including software development, remote health management solutions, commercial property administration, food services, and internet information businesses.
- ISIN
- CNE000000BF3
- Founded
- 1958
- Listed since
- Aug 23, 1993
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.